Replies to post #2102 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>1) …For GTC to be thinking so far into the future when their present is somewhat perilous…<

How, exactly, is the present perilous?

>2) If LFB's majority ownership does not kill any acquisition potential, it does dim that prospect<

How, exactly, is 19.9% a majority?

>3) I believe LFB' voting strength hinders other potential, maybe more lucrative, deals for GTC. Face it, being controlled by a state owned French firm looking for product is not conducive to the time and workforce required for other projects.<

How, exactly, is one board vote in ten control?

>4) …but ask them for a cut in pay for failing with Atryn this past year and a half?<

How, exactly, is getting the first transgenic approval anywhere in the world a failure?

I earnestly await your illuminating reply. Regards, Dew

[Spice is nice]

I would like to add the most relevant reason to reject the LFB proposal:

In my opinion, of course.

GTC is first and foremost a company seeking validation of their platform. This is revealed in their anti-shareholder financings and even the Cox centerfold with a goat. It is revealed with most every deal they have inked, even the Merrimack deal which does not reveal any share of product sales. I believe if this deal is rejected by shareholders GTC will seek to seperate themselves from the controlling public and go private, and at this point I will happily take $2 when the alternative is much less.